Vetoquinol is advising vets and farmers to be on the lookout following the discovery of counterfeit Marbocyl on two farms in Northern Ireland.
The counterfeit product contains an unapproved source of Marbofloxacin in an untested formulation which presents an unknown risk to animal and human health if used.
Vetoquinol has informed the national authorities about this situation. It is illegal either to sell or supply the product or to knowingly buy and/or use it.
The withdrawal period of this counterfeit product is unknown. Should the product be used it could be detected in milk or after slaughter. Vetoquinol advises the veterinary community to be aware of the risk, to carefully check the product packaging before use and to continue to source the product from reputable suppliers.
Vetoquinol urges vets and farmers to take the following actions if you find this product on farm or are approached to purchase it:
Vetoquinol says vets can rest assured that it will do all that is necessary to remove this product from the market.
If you need further information or advice, do not hesitate to contact Vetoquinol on 0800 1698197.
The industry-led Cattle Health and Welfare Group of Great Britain (CHAWG) has published a review which identifies a practical approach to gathering antibiotic usage data on UK cattle farms.
The review outcomes, announced today at a joint conference held by the Responsible Use of Medicines in Agriculture Alliance (RUMA) and the Veterinary Medicines Directorate (VMD), highlight the significant benefits better data could deliver, such as improving the way antibiotics are administered strategically to tackle disease.
But CHAWG’s chair Tim Brigstocke says it’s also important that the industry is able to accurately report usage levels because of the rising levels of antibiotic-resistant bacteria which threaten human health.
"We found that while data is already stored at every vet practice and in every farm medicine book, it currently exists in many different forms. It’s also not collected or collated, and is further complicated by multi-species approvals for many of the antibiotics.
"This means we can’t always be sure in which type of animal a medicine has been used. For example, out of 420 tonnes of animal-authorised antibiotic active substance sold in the UK in 2013, only 14 tonnes was authorised solely for use in cattle. However, 63 tonnes was authorised for multi-species use in food producing animals and within the 217 products included in this, 201 are authorised for use in cattle."
Tim says that with the support of the VMD, which requested the review and will now act as secretariat, CHAWG will set up a working group to implement the report’s recommendations.
The starting point is likely to be the survey of vets carried out by the British Cattle Veterinary Association (BCVA), which formed part of the review. This suggested vets could be using as many as 15 different software programmes to log data, so CHAWG will be working with the BCVA and individual practices to look at how standard sets of data can be anonymised and exported.
"Then we will almost certainly look at how cattle farmers can be supported in migrating records from the physical ‘medicine book’ on the farm, into a spreadsheet or existing cattle management software for anonymous aggregation on a national level.
"There are undoubtedly areas where we can improve the effectiveness of how we use these powerful medicines to improve welfare. But the antibiotic resistance debate is an emotive one and we must also demonstrate accountability to ensure the preservation of antibiotics for future use in humans and animals; any future curbs on usage should be proportionate and informed, and not compromise animal wellbeing."
Mandatory reporting in Europe could be just over the horizon and the European Medicines Agency has focused in the past year on developing a method for data collection on the usage of antibiotics in the EU pig sector. In the UK, the VMD is encouraging the livestock sectors to develop systems appropriate to their own unique circumstances and industry characteristics.
Tim said: "It’s therefore in cattle farmers’ own interests to anticipate the kind of figures it might be asked to supply in the future, and develop a way of collecting that data which suits the way the UK industry works.
"Then we can retain control over the data and the methodology, and ensure the reporting is accurate – and this in turn will help the VMD represent our case better in Europe as this debate continues.
CHAWG says that throughout this project, it will be liaising with others – such as the pig sector – to ensure learnings are shared, duplication avoided and efficiencies realised where possible.
The CHAWG review report is available to download at www.chawg.org.uk.
Animalcare Ltd has launched Marbocare (marbofloxacin) 100mg/ml solution for injection, a third-generation fluoroquinolone for the treatment of E.coli mastitis and bovine respiratory disease (BRD) in cattle, and Metritis Mastitis Agalactia in pigs.
The company highlights the product's unique flexible dosage regimen of once daily injections for 3 days against E.coli mastitis and BRD, plus a single intramuscular (IM) high dose (8mg/100kg) for BRD.
Animalcare says this regimen, coupled with the flexibility of administration afforded by all three injection routes (intravenous IV, subcutaneous SC and IM), a low volume dose and good syringeability, all combine to offer ease of use; resulting in a reduction in handling and less stress for the cattle.
Developed for veterinary use only, Marbocare has broad spectrum activity against Gram+ve and Gram-ve pathogens. Animalcare says the product is especially effective against E.coli mastitis and the key bacterial pathogens associated with BRD, as well as M.bovis.
Marbocare has milk withdrawal times of 36 hours after the last treatment following the 3 day course and 72 hours after a single shot for BRD. Meat withdrawal is 6 days after multiple injections and 3 days after the single shot.
Marbofloxacin has proven efficacy in a comparative international, multi-centre, controlled, randomised field trial1 in 62 dairy cows with E.coli mastitis. Marbofloxacin cure rates were significantly higher than the control product. In respiratory disease it showed a more rapid clinical response in comparison to tilmicosin2, ceftiofur3 and oxytetracycline4. Marbofloxacin was shown to be well tolerated, leading to a fast return to appetite, liveweight gain and associated welfare benefits.
Marbocare is also licensed in the treatment of Metritis Mastitis Agalactia syndrome in pigs, given by IM injection, with a 4 day meat withdrawal.
Tony Liepman, Product Manager from Animalcare said: "Marbocare is competitively priced whether used on its own or alongside a single-dose anti-inflammatory such as Emdocam (meloxicam)."
Marbocare is a POM-V licensed product presented in 50 and 100ml multi-dose vials.
References
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
1,219 farmers took part in the survey: 44% beef and 56% dairy. For the first time, the survey was also tailored for the regions. 488 responses came from famers in England, 380 from Scotland, 164 from Wales and 237 from Northern Ireland.
Boehringer Ingelheim’s Matt Yarnall, who led the project, said: "Headline findings are that farmers have regrets about holding onto persistently infected animals (PIs) which, at the end of the day, no-one should be doing.
"The financial benefit of being free of BVD was estimated as being over £90 per cow per year and when asked what impact BVD has had on their herd, the majority of producers highlighted poor fertility and high levels of disease in the herd.”
Boehringer says the identification of persistently infected animals (PIs) through tag and testing, supported by improved herd biosecurity and vaccination, could cost as little as £10 per cow per year, representing a significant return on investment for a disease with severe financial impact.
Matt said: "Herd biosecurity is also hugely variable. The most commonly selected response was operating a closed herd but, as most practitioners will know, the definition of a true closed herd and the real-life execution of that can be two very different things."
Highlighting one of the other major challenges for producers in cattle-dense areas, results from Scotland that showed that 51% of farmers with neighbouring cattle are worried about their neighbours' BVD status.
Matt said: "Perhaps the most alarming finding was the lack of awareness of the intricacies of some BVD vaccination courses, especially around when they need to be restarted, in order to achieve the protection needed."
2017 survey data from last year showed that 71% of producers were failing to achieve adequate protection when using a BVD vaccine that requires a booster six months after the primary course.
Boehringer says the results showed this is mostly down to not properly understanding the exact nature of the timings for the two-dose primary course, dates of service and calving and then the booster date.
Matt added: "For any practitioner advising clients, the 2018 finding that a shocking 85% haven’t restarted a vaccination course when the majority should have done, should ideally serve as a clear call to action."
For more information about the findings of the National BVD Survey, email bvdzero.uk@boehringer-ingelheim.com.
The app, which works on tablets and smartphones, allows vets to e-mail audit results directly to clients following an interactive calf health assessment at the farm.
MSD Animal Health’s youngstock marketing manager Robert Simpson said: “Our new app allows both parties to explore, record and score calf health performance across five core areas to identify the strengths and weaknesses of any rearing unit’s environment and processes.
“Working through a series of 10 questions within each core area – designed to tease out where a rearing unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to monitor progress against agreed targets”.
For more information about the app, contact your MSD account manager.
The product was one of eight NSAIDS that had been suspended following a European ruling that an excipient, diethanolamine, may pose a risk to human health.
Allevinix is licensed for both intravenous (I/V) and intramuscular (I/M) administration over one to three days in cattle. It has a dose rate of 4ml per 100kg liveweight in cattle, and milk withdrawal times of 24 hours after I/V injection and 36 hours after I/M injection.
Ceva says Allevinix reaches peak plasma levels (CMax) approximately 30 minutes following I/M injection. It is available in 100ml and 250ml vials.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: "Allevinix is the only flunixin licensed for both intramuscular and intravenous administration in cattle and provides both vets and farmers with a cost-effective, fast-acting and versatile NSAID that is a useful addition to the range of NSAID options available."
For more information, contact your Ceva account manager, email cevauk@ceva.com or call the ruminant marketing department at Ceva on 01494 781510.
US-based Life Technologies has launched a new PCR-based test system which, according to the company, allows large numbers of pigs to be screened more quickly and cost-effectively for a range of common pathogens, such as PRRSV, SIV and PCV2.
The system uses samples of oral fluids which can be obtained by leaving a cotton rope in each pen for pigs to chew on. After 20 minutes or so, the rope can be retrieved and the saliva and gingival crevicular fluid squeezed into a sample bag and represents a pooled sample from the group.
Studies have demonstrated that oral fluid samples collected in this way can form the basis of a quick and cost-effective method for screening a range of common viral pathogens. The samples were tested using a commercially available sample preparation and real-time PCR test system which can isolate and identify viral nucleic acid in a matter of hours.
For PRRS, pooled samples of oral fluids were collected from groups of experimentally infected pigs using the rope technique, along with serum samples from each individual pig on the same days. Both serum samples and oral fluids were processed using the same Applied Biosystems preparation system and real- time PCR test, both of which were supplied by Life Technologies. The results showed that PRRSV nucleic acid was detectable in both serum and oral fluid samples from the day of infection through to 40 days after infection.
For PCV2, 24 pigs that were free of PRRSV and SIV were divided into 4 pens in separate rooms, and challenged with two different virus strains (PCV2a and PVC2b) at different times. One pen acted as a (non-challenged) control. Oral fluids were collected regularly up to 140 days after initial challenge and tested using real-time PCR. High titres of PCV2 were detected from day 12 to day 28 post infection and virus was detectable throughout the entire testing period (days 2 to 98).
For SIV, a total of 180 spiked oral fluid samples were tested using real-time PCR, and subtyping reagents were also used to identify haemagglutinin and neuraminidase subtypes. The results showed that SIV nucleic acid was detectable in oral fluid samples spiked with high, medium and low copy numbers of SIV, and all positive samples could be successfully sub-typed.
Christina Boss, European Professional Service Veterinarian for Life Technologies said: "Collecting samples in this way is far less invasive for the pigs and so avoids unnecessary stress. And because all of the pigs will chew on the rope, it provides a very broad sample from the group, which is the key to assessing overall herd health. In addition, if the pooled sample provides a positive result, then the animals in that pen can be tested individually to identify those that are infected.
"These results show that the simplicity of oral fluid sampling, combined with the speed and sensitivity of a PCR-based system, provides a practical and cost- effective way of monitoring large numbers of pigs for common virus pathogens.
"The use of a semi-automated, PCR-based diagnostic system means that nucleic acid purification can be achieved in just 25 minutes and results from the real-time PCR available in 90 minutes. The molecular test is very specific and reliable, so the veterinarian can initiate individual testing as quickly as possible and make confident recommendations to the producer."
According to Life Technologies, screening for PRRS using samples of oral fluids has been gaining popularity over recent years because large numbers of pigs can be tested without increased cost or labour. The new research is due to be presented as a poster at the ESPHM meeting in Bruges in April.
The role was created last November when the Animal & Plant Health Agency (APHA) started allowing para-professional staff to support vets in carrying out TB testing in England.
UK Farmcare says there are now 49 fully authorised ATTs in England with another 21 TB testing under veterinary supervision and three undergoing the theory part of the training.
To become an ATT, applicants must be at least 18 years old, hold a valid UK driving licence and passport, possess a clean criminal record and then be approved by the APHA. Applicants also need at least three graded GCSEs or equivalent in English, Maths and a science or food production subject and at least six months cattle handling experience.
https://ukfarmcare.com/an-introduction-to-the-att-role.
Bimeda UK has announced that Endofluke 100mg Oral Suspension has been approved for use in dairy cows, with a milk withdrawal period of 45 days + 48 hours.
Endofluke is licensed for use in cattle and sheep and its active ingredient, triclabendazole (100mg/ml) kills all three stages of liver fluke.
Bimeda UK Sales Manager, Andrew Lane said: "This is great news for the UK's dairy farmers. Endofluke has long been favoured by British & Northern Irish farmers as a liver fluke treatment, due to its ability to offer complete chronic and acute fluke control in both sheep and cattle. It is proven to be highly effective against early-immature, immature and adult liver fluke, and to now be able to extend these benefits to dairy cows, is fantastic news for the UK's dairy farmers."
Endofluke is a POM-VPS product.
For more information, visit www.bimeda.co.uk or contact Bimeda UK Sales Manager Andrew Lane, on alane@bimeda.com or on 07917 208524.
CEVA Animal Health has announced that its live enzootic abortion vaccine, CEVAC® Chlamydophila, now has an added benefit. It can be used simultaneously with the only available toxoplasmosis vaccine. According to CEVA, infectious abortion, particularly enzootic abortion (Chlamydiosis), has been known to wipe out up to 50% of lambs. Strategic use of CEVAC® Chlamydophila, a live enzootic abortion vaccine, can not only prevent abortion but can also control excretion and the threat of infection.
The company says: "CEVAC® Chlamydophila makes practical and economic sense. A vaccination every four years will help your clients’ flocks remain chlamydiosis-free and the cost of treatment should work out at well under 75p per sheep per year. This is a tiny investment for your clients, to prevent the financial loss of an abortion. The fact that the product can now be used on the same day as the toxoplasmosis vaccine means that is now one of the most convenient and affordable methods currently available."
Ideally routine preventative measures should be taken prior to mating and when new sheep are introduced to the flock, to ensure abortion and infection rates always remain as low as possible.
All animals should be vaccinated in the first year, with replacements being vaccinated from six months of age, at least four weeks prior to tupping.
CEVAC® Chlamydophila is quick and easy to administer, using the special, multi-dose injector gun. One bottle of vaccine contains enough for 20 doses.
For further product information contact your local CEVA representative or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG or visit the website at http://www.ceva.uk.com/
The new Flock Health Checklist is designed to helps practitioners assess performance across the three crucial time periods and two key management processes which have an impact on the success of sheep enterprises.
Dr Kat Baxter-Smith, veterinary adviser with MSD Animal Health said: “We have developed this new performance checklist drawing on specialist sheep vet working experiences, clinical research studies, economic data and industry recommendations.
"For example, the pre-breeding period is a great time to make sure ewes and rams are as fit and healthy as possible.
"Good practice and preparation in this area will go a long way to minimising stress and problems during a busy lambing period.”
Late pregnancy and lambing period is also a vital time – and is the busiest few weeks on any sheep farm.
Kat added: “Having pre-agreed protocols for this important period in the sheep farming calendar – and keeping a record of issues that arise – will go a long way to making sure subsequent lambing seasons go as smoothly as possible.”
Growth, weaning and sale is the third crucial time period and the Flock Health Checklist incorporates an additional series of audit-based questions designed to pinpoint system strengths and weaknesses.
The Flock Health Checklist also enables vets to ask a series of questions covering two key management processes: disease management and biosecurity; and how flock performance is currently monitored.
Kat said: “Working through a series of 10 questions within each of the three crucial time periods and two key management processes – designed to tease out where a sheep unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to montor performance against agreed targets.
“Similar types of checklist have been available to dairy youngstock rearing units and beef suckler herds for a couple of years now, with several vets reporting that these tools have proved integral to their productivity improvement work with farmer clients.
"Use of this checklist-based approach is also helping better implementation of preventative health practices such as vaccination. We hope this latest tool will help the GB sheep industry similarly.”
For further information, contact your local MSD Animal Health account manager.
AmpliSpec LAB Mastitis uses isothermal amplification technology, which means laboratories can use less expensive equipment.
It also uses the company's lyophilised bead platform, designed to make the test stable and easy to use.
Biotangents says its new test will offer notable cost, speed and accuracy benefits over the traditional culture and PCR testing used by animal health laboratories and veterinary clinics around the world.
CEO Fiona Marshall said: “With 93% sensitivity and 95% specificity, this is a highly sophisticated assay that will help farmers, vets and laboratories to better treat mastitis.
http://www.biotangents.co.uk
The award, which is sponsored by Zoetis, was given online this year at an event hosted by sports television presenter Mark Durden-Smith and Chloe Ryan, the editor of Poultry Business.
William was brought up on a sheep farm in Nottinghamshire and as a youngster bred rare breed poultry, selling eggs to local people in the village. He graduated at Nottingham University, did a poultry internship with a practice in the North West and worked there initially. Four years ago, he set up his own practice Avivets, at High Legh in Cheshire, dedicated to the poultry and game bird sector. He guest lectures at the Universities of Nottingham and Surrey and is an official veterinarian for avian exports. He sits on the RSPCA’s technical standards advisory board and was recently appointed veterinary advisor for the NFU poultry board.
Chloe Ryan said he had impressed the judges ‘with his enthusiasm for poultry veterinary knowledge and entrepreneurship. He has shown an excellent level of dedication, enriching his experience and qualifications through continuous professional development to farms and flocks as evidenced by glowing praise from a long list of clients.’
Lucy Berriman, Zoetis UK poultry national account manager, said: “Zoetis is proud to be sponsors of this new award for the industry’s poultry vets.
"It gives hardworking individuals the chance to shine and illustrate their commitment to the poultry industry. Congratulations to Will for this fabulous achievement, and well done to the other two finalists."
The other finalists were Helena Brewer, who joined the Poultry Health Services team at Sheriff Hutton, near York, after studying at the Royal (Dick) School at Edinburgh and the Royal Veterinary College, and Henry Lamb, who has worked at Crowshall Veterinary Services in Norfolk since graduating at the Royal Veterinary College.
The campaign aims to demonstrate the direct link between proactive parasite management and flock performance, while also providing tools for vets to engage farmers in conversations around worm control on-farm.
Fiona Hutchings (pictured), ruminant technical manager at Elanco Animal Health, said: “The Better Butt campaign encourages vets and farmers to work together to strategically plan mid- to late-season break doses and quarantine treatments, using the newer group wormers, such as Zolvix, to minimise worm burdens and support healthy growth.”
Fiona says the campaign advises farmers to move away from solely relying on visible signs of worm burdens before taking action, because lamb performance has already been compromised by the time visible signs are present: “Even the best stockman, or experienced sheep person, will struggle to spot an early worm burden, and by the time it’s visible, the burden is usually high.”
“Reductions of up to 50% in growth rates can occur before visible symptoms appear1, resulting in extended finishing times and higher feed demands.”
The campaign uses a traffic light system to help farmers understand worm burden impacts and encourages treatment interventions when animals tip into the amber zone.
“When lambs have a low worm burden, they’re in what we call the green zone, which means they have enough energy for both maintenance and growth.
“However, when this burden increases and they tip into the amber zone, this is when you’ll start noticing changes in the time taken for lambs to finish as worms begin to damage the gut meaning the lambs can’t utilise their feed as well.”
Fiona added: “Many sheep farmers are already doing a brilliant job of managing their stock, but we want to show them that there could be an opportunity to unlock more potential from their flock.”
https://farmanimal.elanco.com/en_gb/sheep/sheep-worms/zolvix-worth-every-penny
Dickson Company has launched the Dickson Alarm Thermometer, a tool to ensure that vaccine and drug storage temperatures in both refrigerators and freezers fully comply with regulatory requirements.
Featuring tamper-resistant audible and visual alarms, the Dickson Alarm Thermometer costs US$59 for a two probe model (MM125) that can monitor both refrigerators and freezers simultaneously and US$49 for a single probe model (MM120).
Both the MM125 and MM120 models are continuous, calibrated and certified thermometers that are able to monitor temperatures in the -58 to +158°F (-50 to +70°C. For more technical details on Dickson Alarm Thermometers see (www.dicksondata.com/product/model_MM120.php).
Product inquiries can be directed to Dickson customer service at dicksoncsr@dicksondata.com, or calling 800-757-3747 or +1-630-543-3747 outside the US, FAX +630-543-0498 or by writing Dickson, 930 South Westwood Avenue, Addison, IL 60101, USA.
Bovilis Nasalgen-C can be used for the active immunisation of calves from the day of birth onwards to reduce clinical signs of upper respiratory tract disease and nasal viral shedding from infection with BCoV.
MSD says respiratory disease in UK calves is widespread and comes at a high cost from an emotional and business productivity perspective.
It is also continually highlighted as a critical area for overuse of antibiotics.
Despite all this, there is an under use of vaccination in the UK cattle sector1.
Speaking at BCVA last week, Paul Burr MRCVS, director of Biobest Laboratories said: “Recent UK studies show bovine coronavirus being the most prevalent virus found in routine disease screening and nasal swab samples taken during a bovine respiratory disease outbreak.
"BCoV was found in 39% of over 400 nasal swab samples taken between 2020 and 2022 from BRD affected cattle on UK farms2.”
Kat Baxter-Smith, veterinary adviser with MSD Animal Health, said: “Whilst the pathogenicity of BCoV within the BRD complex remains an unknown quantity, its ubiquitous presence in the UK cattle population – and the recent human experience of coronavirus as a significant respiratory pathogen – suggests a need for a re-evaluation of BRD control by vets and farmers.
“Just as coronavirus is a pathogen associated with the common cold and Covid-19, BCoV is a proven pathogen that directly impacts the calf respiratory tract.
"Consequently, the availability of this new BRD vaccine presents veterinary professionals with another tool in their armoury to improve control of this costly disease.
“If diagnostics suggest BCoV is implicated in any BRD problem, the availability of Bovilis Nasalgen-C allows UK cattle farmers to effectively administer protection for young calves via a single 2ml intranasal dose that can quickly reach the site of action.
"This will support the development of immunity against BCoV early in life, the onset of which starts five days after administration and has a 12-week duration.”
Bovilis Nasalgen-C comes can be used on the same day with Bovilis INtranasal RSPÔ Live, which offers protection against both Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3).
Bovilis Nasalgen-C can be stored for up to 24 hours at room temperature after reconstitution, can be given to cattle using a syringe or applicator device and is available in one, five and 20 dose packs, suitable for both small and large herds.
References:
Krka’s Farm Key Account Manager Charlotte Read said: “BRD remains a priority issue on farm and advising farmers on the management of BRD risks, and treatment options when needed, is a key task for farm vets.
"Flovuxin’s combined formulation is a high efficacy BRD treatment acting within six hours1, to improve treatment outcomes.”
Reference
The step-by-step guide offers guidelines to help farmers improve their herd's mobility.
It highlights the importance of implementing a robust and ongoing treatment plan to improve cow comfort and reduce lameness in the short-term, which will lead to increased production and herd welfare in the longer-term.
The guide includes advice on reviewing a whole herd by an independent RoMS (Register of Mobility Scorers) accredited mobility scorer, seeking veterinary advice or contacting a mobility mentor (someone who has been trained to deliver the ADHB Healthy Feet Programme) if lesions are identified, treating within 48 hours of identification with a combination of trim, block, topical antimicrobial spray and non-steroidal anti-inflammatory (NSAID), as appropriate, and the importance of ongoing treatment, prevention and monitoring every fortnight.
The guide also includes tips for the successful use of NSAIDs, which include the importance of using a NSAID with a zero milk withhold.
There are four lameness management videos which were produced in collaboration with James Wilson BSc (Hons) PhD, a foot health consultant from Herd Health Consultancy and include contributions from Alex Burrows, professional foot trimmer and Chair of the National Association of Cattle Foot Trimmers (NACFT), Dave Bacon, a dairy farmer from Gleadthorpe Farm in Nottinghamshire, Shannon Trinder, assistant herdsperson at Gleadthorpe Farm and Harry Walby BVetMed MRCVS, veterinary surgeon and ruminant technical advisor at Ceva Animal Health.
They cover the benefits of regular mobility scoring, prioritising mobility and lameness prevention in heifers and maintaining lameness management success with practical and effective lameness treatment and prevention programmes.
www.wavegoodbyetopain.co.uk/pdf/step-by-step-guide.pdf.www.wavegoodbyetopain.co.uk/training-videos.html.
The ‘Midgeater' device introduced by Calor in 2003 to combat biting midges causing irritation to humans, has now been successfully tested by leading scientists as a monitoring device in the fight against bluetongue.
Leading midge scientist Dr Alison Blackwell, who is the Managing Director of University of Edinburgh based Advanced Pest Solutions, presented her company's findings in her keynote speech to the Royal Entomological Society in Belfast on November 19th.
The current method of trapping midges when monitoring the deadly bluetongue virus is a light trap, but Alison and her team have established that a modified Midgeater can be more effective in catching the main midge species that carry the virus.
Alison said: "During trials this year, we found that Calor fuelled Midgeater traps modified with a simple ‘black' light source and fitted with an octenol / ammonia bait, proved to be far more effective at catching the main species of midge known to carry the bluetongue virus than the light traps which are currently used to monitor midge populations in relation to the disease".
Farmers throughout the UK recently commenced a vaccination programme to protect their animals from the only strain of the bluetongue virus that has so far been encountered in the UK, serotype 8, but there is still a real need to carefully monitor biting midge populations, as other strains of the virus are approaching our shores.
Alison added: "In the last few weeks serotype 1 and serotype 6 have been found in Northern Europe and there are currently no vaccines available in the UK for these types of the bluetongue virus, so it is important that we remain vigilant and monitor midges throughout the UK".
Advanced Pest Solutions have tested their modified Midgeater traps in England and Wales. The English, project which was carried out at a specialist bull breeding facility, also included the use of the Barrfly air curtain, from fellow Scottish business Innovent.
Alison explained: "Innovent's air curtain is designed to prevent midges passing through it into sensitive areas. The insects simply aren't strong enough to fly through the air currents it produces.
"The air curtain, combined with the Calor supplied traps and APS's consultancy and analysis creates a comprehensive ‘assess, protect and stop', midge management system that businesses can use to reduce the exposure to the risks of midge borne diseases."
In the Somerset cull area, TB incidence has fallen from 24% before culling started to 12% in year four of the cull, while in Gloucestershire it has fallen from 10.4% to 5.6%.
The Government says the findings are in line with expectation based on the scientific evidence from the Randomised Badger Culling Trial which underpins the approach to tackling bovine TB – and demonstrate progress is being made in delivering the 25-year TB eradication strategy in England to rid our farmers of the impacts of this terrible disease.
Defra has also announced additional measures being taken to help control the disease, including licences for badger control in 11 new areas and the opening of a new round of applications for the Badger Edge Vaccination Scheme grants.
Farming Minister George Eustace said: "Bovine TB remains one of the greatest animal health threats to the UK. There is no single measure that will provide an easy answer which is why we are committed to pursuing a wide range of interventions to protect the future of our dairy and beef industries and eradicate the disease within 20 years.
"No one wants to be culling badgers forever so the progress reported today is encouraging."
BVA President John Fishwick said: "We continue to support a comprehensive and evidence-based approach to tackling bovine TB, including the use of badger culling in a targeted, effective and humane manner. TB is a devastating disease and we welcome the positive results emerging in Somerset and Gloucestershire, where licensed culling has now been in place for four years. The recent results in Dorset, indicating a slight upward trend in the incidence of bovine TB, present some cause for concern and we would like to see further investigation of the cattle and wildlife situation in that area.
"BVA supports the principle of badger controls within the Low Risk Areas (LRAs) of England where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy. We are largely reassured by the greater clarity provided on the decision-making process on how and where badger controls will be introduced in the LRAs. We recognise the expertise and professional judgement of veterinary and scientific colleagues in government who have made the decision to extend the cull in this area, but we would welcome further evidence regarding the level of TB infection in the wildlife reserve in Cumbria as this becomes available.
"Halting the spread of bovine TB is essential and it is vital that we use every available tool in the toolbox to support the Government’s aim to make England TB free. We therefore welcome both the introduction of tighter cattle controls where needed and the re-commencement of the Badger Edge Vaccination Scheme, particularly if used as a ‘firebreak’ to mitigate the spread of the disease into the low risk areas. We would also like to see a commitment to funding of further research in this area."
Photo: Coatesy/Shutterstock
CEVA Animal Health has extended its range of injectable anti-infectives with Florkem, a Florfenicol-based antimicrobial for the treatment of respiratory tract infections in cattle and pigs.
According to the company, Florfenicol shows a strong in vitro bactericidal activity against the most common respiratory tract pathogenic bacteria and can be used as a time or dose-dependent bactericidal depending on the target. It also offers very good diffusion in most tissues for an efficient response.
CEVA says Florkem® is very convenient to use: a specifically developed formulation provides for better syringeability, in both warm and cool temperatures, making administration quicker and easier. It is presented in an ergonomic CLAS vial, which is shock resistant, light and easy to handle in the field. This means fewer breakages, which can reduce costs while maintaining efficacy.
For further product information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
Defra has announced that the Bluetongue Protection Zone will be extended again on Monday 7 July, following the delivery by Intervet of almost 2 million additional doses of Bluetongue vaccine. Vaccination is only permitted within the Protection Zone. In accordance with the Bluetongue vaccination plan, the Protection Zone will be extended to cover all of the East Riding of Yorkshire (including the City of Kingston upon Hull), South Yorkshire (made up of the metropolitan boroughs of Barnsley, Doncaster, Rotherham and Sheffield), Gloucestershire (including the unitary authority of South Gloucestershire) and Warwickshire. Defra will continue to roll out vaccination as vaccine is delivered, in line with the vaccination roll-out plan. The additional vaccine is available for use in the existing Protection Zone from today. Livestock keepers in the areas coming into the Protection Zone will be able to obtain the vaccine from Monday. However, they are encouraged to order vaccine so that they can protect their livestock at the earliest opportunity. Protection Zone restrictions will apply to those keepers coming into the extended zone. Animals can only be moved out of the Protection Zone if they are vaccinated, naturally immune or moving for slaughter, subject to meeting certain conditions. Animals will also be able to be moved between the Protection Zones in Wales and England, subject to the conditions on the transit licence.
The new 10ml (10-dose) and 100ml (100-dose) packs of Ingelvac PRRS EU are available now, and will complement the existing 50ml (50-dose) packs.
Callum Blair MRCVS, Swine Brand Manager at Boehringer Ingelheim, said: "Nobody likes to end up with part used bottles of any vaccine that then have to be discarded. The addition of Ingelvac PRRS EU 10-dose and 100-dose packs will provide choice for different sized units and help reduce wasted doses."
For more information, visit www.prrs.com.